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OligodendrocytesMultiple system atrophy (MSA) is a rare neurodegenerative disease of undetermined cause manifesting with
progressive autonomic failure (AF), cerebellar ataxia and parkinsonism due to neuronal loss in multiple brain
areas associated with (oligodendro)glial cytoplasmic α-synuclein (αSYN) inclusions (GCIs). Using proteolipid
protein (PLP)-α-synuclein (αSYN) transgenic mice we have previously reported parkinsonian motor deﬁcits
triggered by MSA-like αSYN inclusions. We now extend these observations by demonstrating degeneration of
brain areas that are closely linked to progressive AF and other non-motor symptoms in MSA, in (PLP)-αSYN
transgenic mice as compared to age-matched non-transgenic controls. We show delayed loss of cholinergic
neurons innucleus ambiguus at 12 months of age aswell as early neuronal loss in laterodorsal tegmental nucleus,
pedunculopontine tegmental nucleus and Onuf's nucleus at 2 months of age associated with αSYN oligoden-
droglial overexpression.We also report that neuronal loss triggered byMSA-likeαSYN inclusions is absent up to
12 months of age in the thoracic intermediolateral cell column suggesting a differential dynamic modulation of
αSYN toxicity within the murine autonomic nervous system. Although the spatial and temporal evolution of
central autonomic pathology in MSA is unknown our ﬁndings corroborate the utility of the (PLP)-αSYN
transgenic mouse model as a testbed for the study of oligodendroglial αSYN mediated neurodegeneration
replicating both motor and non-motor aspects of MSA.ogy, Department of Neurology,
ck, Austria. Fax: +43 512 504
enning).
-NC-ND license. © 2010 Elsevier Inc. Open access under CC BY-NC-ND license. Introduction
Progressive autonomic failure (AF) including orthostatic hypoten-
sion, urogenital and sudomotor failure frequently accompanies or
precedes the motor features of multiple system atrophy (MSA)
(Stefanova et al., 2009a; Wenning and Stefanova, 2009). The presence
of AF is therefore obligatory for a diagnosis of clinically probable MSA.
(Gilman et al., 2008; Stefanova et al., 2009a; Wenning and Stefanova,
2009). The underlying neuropathological substrate of MSA involves a
system-bound neurodegeneration that is associated with α-synuclein
(αSYN)-positive (oligodendro)glial cytoplasmic inclusions (GCIs)
(Papp and Lantos, 1994; Jellinger, 2003). Previous work has demon-
strated that AF in MSA is associated with neuronal loss in selected
regions of the autonomic nervous system (ANS) (Table 1). Clinicopath-
ological studies have linked orthostatic hypotension with degeneration
of preganglionic sympathetic neurons in the intermediolateral columns
(IML) of the spinal cord (Oppenheimer, 1980; Wenning et al., 1997),with failure of supraspinal cardiovascular control due to degeneration of
catecholaminergic neurons in the ventrolateral medulla and locus
coeruleus as well as preganglionic cholinergic neurons of nucleus
ambiguus (NAmb) (Benarroch et al., 2002, 2006; Benarroch, 2003).
Additional non-motor features of MSA including REM sleep behaviour
disorder, erectile dysfunction and bladder hyperactivity appear to be
related to loss of neurons in pedunculopontine tegmental nucleus (PPT)
and laterodorsal tegmental nucleus (LDT) (Schmeichel et al., 2008; Gaig
et al., 2008; Salas et al., 2008; Koyama et al., 1999). Anal and urethral
sphincter failure in MSA has been associated with loss of neurons in
Onuf's nucleus of the spinal cord (Mannen, 2000; Yamamoto et al.,
2005).
Recently, transgenic mouse models, overexpressing human αSYN
under speciﬁc oligodendroglial promotors have been developed to re-
produce the speciﬁc GCI pathology ofMSA (Kahle et al., 2002; Stefanova
et al., 2005a; Yazawa et al., 2005; Shults et al., 2005). Abnormal motor
behaviour may be striking in these models and appears to relate to
neurodegenerationdependingon the speciﬁc oligodendroglial promoter
(Stefanova et al., 2005b). To our knowledge, brain regions associated
with the non-motor symptomsofMSAhave not been investigated in the
αSYNMSAmodels so far.Herewe report thatNAmb, PPT, LDTandOnuf's
nucleus undergo progressive degeneration in (PLP)-αSYN mice, thus
directly and for the ﬁrst time linkingαSYN toxicity with vulnerability of
central autonomic and related non-motor regions.
Table 1
Suggested clinicopathological correlations in human MSA and the relevance of the
(PLP)-αSYN mouse model. (Wenning et al., 1997; Yoshida, 2007; Benarroch, 2003;
Schmeichel et al., 2008; Yamamoto et al., 2005; Stefanova et al., 2005a,b).
Clinical presentation
of MSA
Pathological ﬁndings in human
MSA (including neuronal loss
and GCIs)
Pathology in the
(PLP)-αSYN mouse
Neuronal loss GCIs
Parkinsonism Substantia nigra + +
Striatum − +
Pedunculopontine
tegmental nucleus
+ +
Ataxia Olivopontocerebellar atrophy − +
Orthostatic hypotension Intermediolateral columns − +
Ventrolateral medulla
(C1 and A1)
Na +
Dorsal vagal nucleus Na +
Locus coeruleus + +
Nucleus ambiguus + +
Urinary dysfunction Suprapontine micturition centers Na +
Pontine micturition center Na +
Intermediolateral columns − +
Laterodorsal tegmental nucleus + +
Onuf's nucleus + +
Laryngeal stridor Nucleus ambiguus + +
REM sleep behaviour
disorder (RBD)
Laterodorsal tegmental nucleus + +
+, reported; −, not reported; Na, not analysed.
Fig. 1. (A) Tail clip PCRwas applied to genotype (PLP)-α-SYN transgenicmice used in this
study (i.e. sixmice at 2 months of age and6mice at 12 months of age) by applyingprimers
whichampliﬁeda450 bp fragmentof thehumanα-synuclein (AD,distilledwater;−, non-
transgenic negative control; +, positive control of the reaction for human αSYN). (B)
Immunohistochemistry with 15G7 antibody against human α-synuclein demonstrated
strong expression of the transgenic protein in the spinal cord of (PLP)-α-SYN transgenic
mice. Inset: The colocalisation of 15G7 (red) and CNP (green) conﬁrmed the expression of
human α-synuclein in oligodendrocytes of (PLP)-α-SYN transgenic mice (bar, 10 µm).
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Animals
The generation and characterisation of (PLP)-α-SYN mice was
previously described (Kahle et al., 2002). All experiments were
performed in accordance with the Austrian law and permission for
animal experiments of the Federal Ministry for Education, Science,
and Research of Austria. (PLP)-α-SYN transgenic mice were bred at
the Animal Facility of the Innsbruck Medical University and
genotyped by tail clip PCR applying human αSYN speciﬁc primers
which ampliﬁed a 450 bp fragment. In the present study we used
homozygous (PLP)-α-SYN transgenic mice and non-transgenic
control mice at 2 months of age and 12 months of age (for each
experimental group n=6, always 3 male and 3 female per group)
(Fig. 1A). Animals were housed under a 12-h light/dark cycle with
food andwater available ad libitum. All efforts were made to minimise
the number of animals used and their suffering.
Tissue processing
Animals were perfused transcardially with 4% paraformal-
dehyde under deep thiopental anaesthesia. Brains and spinal cords
were removed, postﬁxed in the same ﬁxative overnight at 4 °C, and
cryoprotected with 20% sucrose. Brains and spinal cords were slowly
frozen and kept at−80 °C until further processing. Four series of 40 µm
sections throughout the whole brain and 5 series of 50 µm sections
throughout the thoracic and lumbosacral spinal cord were cut on a
cryostat (Leica, Nussloch, Germany). We selected ﬁve nuclei (IML, LTD,
PPT, NAmb, Onuf's nucleus) for morphometry based on the following
criteria: 1) established role in human and rodent autonomic function,
2) evidence of αSYN pathology in human MSA. Thoracic series of spinal
cord sections underwent cresyl violet (CV) and acetylcholine esterase
(AchE) staining todeﬁne theborders anddeterminenumberofneurons in
the IML. A series of brain sections (bregma +4.04 - bregma +7.50)
underwent immunohistochemical staining for choline acetyl transferase
(ChAT), to visualise cholinergic neurons of NAmb, LDT and PPT according
to a standard protocol. Shortly, endogenous peroxidase activity was
quenched in H2O2. After normal serum blocking sections were incubatedwith goat anti-ChAT antibody (Chemicon International) overnight at 4 °C,
followed by incubation in biotinylated anti-goat IgG (Vector Laboratories,
CA).After incubation inVectastainABC reagent (VectastainABCkit, Vector
Laboratories, Burlingame, CA), the immunohistochemical reaction was
developedwith3,3′-diaminobenzidine(DAB)andsectionsweremounted
onto gelatine-coated slides, dehydrated and coverslipped with Entellan.
Immunohistochemistry for human αSYN was performed using the rat
monocloncal anti-human synuclein 15G7 antibody (Kahle et al., 2001)
(generously provided by PJ Kahle, Tübingen) to conﬁrm transgenic
expression of the protein. Oligodendroglial expression of human αSYN
was conﬁrmed by double immunoﬂuorescent staining with monoclonal
rat 15G7 human αSYN antibody and monoclonal mouse 2',3'-cyclic
nucleotide3'-phosphohydrolase (CNP)antibody (Abcam,Cambridge,UK)
followed by Cy3-conjugated rabbit anti-rat IgG (Jackson Immuno
Research Laboratories, West Grove PA, USA) and Alexa-ﬂuor 488-con-
jugated goat anti-mouse IgG (Molecular Probes, Leiden, the Netherlands)
respectively.Image analysis
All morphometric analyses were done by a blinded observer applying
a computer-assisted image analysis system (Nikon E-800 microscope,
Nikon digital camera DXM 1200; Stereo Investigator Software, Micro-
BrightField Europe e.K., Magdeburg, Germany). The optical fractionator
(West et al., 1991) was used to estimate total number of neurons in
the IML of thoracic spinal cord and number of cholinergic neurons in
NAmb (Bregma −6.64 mm - −7.48 mm), LDT (Bregma −4.96 mm -
−5.52 mm), and PPT (Bregma −4.16 mm - −4.96 mm) – borders
determined as in themouse brain atlas (Franklin and Paxinos, 1997). The
mouse analogue of the human Onuf's nucleus was determined according
to the mouse spinal cord atlas (Watson et al., 2008). Neurons in lamina
9 innervating the external urethral sphincter (ExU9) and the external
anal sphincter (ExA9) were counted in sections at the level of L6.
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Statistical analysis was performed using the Graph Pad Prism
Software. Data are presented asmean±SEM. The data for the analogue
of the Onuf's nucleus, IML, NAmb, LDT and PPT were compared by two
way ANOVA for genotype and age effects followed by post hoc
Bonferroni test to compare groups individually. P value of b0.05 was
considered signiﬁcant.
Results
Human αSYN in oligodendrocytes was detected throughout the
whole CNS of (PLP)-αSYN mice as determined by co-expression with
the oligodendroglial marker CNP (Fig. 1B). In all cases non-transgenic
animals had no human αSYN gene expression as determined by tail
clip PCR and negative immunostaining for human αSYN (data not
shown).
At 2 months of age no signiﬁcant difference was observed between
transgenic and non-transgenic mice in the number of cholinergic
neurons in NAmb. However, (PLP)-αSYN transgenic mice at 2 monthsFig. 2. Immunolabelling for ChAT of the nucleus ambiguus (A), laterodorsal tegmental nuc
transgenic (tg) mice with oligodendroglial expression of human αSYN was performed. M
genotype-related loss of neurons in nucleus ambiguus (B), laterodorsal tegmental nucleusof age showed signiﬁcant loss of cholinergic neurons in LDT and PPT
compared to age-matched non-transgenic controls. At 12 months
there was progressive brainstem pathology in the (PLP)-αSYN trans-
genic mice with neuronal loss affecting all cholinergic nuclei analysed
(NAmb, LDT and PPT, Fig. 2). Preganglionic sympathetic neurons in
the IML were reduced at 12 months in both transgenic and non-
transgenic mice without any signiﬁcant genotype effect (Fig. 3A and
B). Further analysis of the lumbosacral region of the spinal cord
showed an early loss of neurons in the mouse analogue of Onuf's
nucleus that was associated with transgenic oligodendroglial αSYN
overexpression and further augmented at 12 months.(Fig. 3C and D).
Interestingly, non-transgenic mice showed an age-related increase in
the number of motoneurons in Onuf's nucleus. Similar observation
was previously reported in association with the breeding status of
rodents (Seney et al., 2006) suggesting that both male and female
breeders present with increased numbers of motoneurons in Onuf's
nucleus. In this context, our results indicate that oligodendroglial
αSYN overexpression in (PLP)-αSYN transgenic mice might result in
disruption in the normal functional neurobiology of the analogue of
Onuf's nucleus.leus (C) and pedunculopontine tegmental nucleus (E) of non-transgenic (non-tg) and
orphometric analysis of ChAT-immunoreactive (ChAT-IR) neurons indicated age- and
(D) and pedunculopontine tegmental nucleus (F). (*pb0.05, **pb0.01, ***pb0.001).
Fig. 3. (A) Thoracic spinal cord was processed for acetylcholinesterase (AChE) and cresyl violet (CV) histochemistry to localise the intermediolateral column (IML, encircled).
(B) Morphometric analysis indicated age-related loss of preganglionic sympathetic neurons in IML with no signiﬁcant difference between non-transgenic (non-tg) and transgenic
(tg) mice with oligodendroglial expression of humanαSYN both at 2 and 12 months of age. (C) Themouse analogue of the human Onuf's nucleus (ExA9 and ExU9) in lamina 9 at the
level of L6 (Jacob et al., 2005) was visualised in cresyl violet staining. (D) Signiﬁcant loss of neurons in the Onuf's nucleus analogue was detected in transgenic versus non-transgenic
mice both at 2 and 12 months of age. Age-related increase in the number of motoneurons was found in Onuf's nucleus of non-tg animals but not detected in tg mice with αSYN
pathology (**pb0.01; *** pb0.001).
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In this study we investigated whether pathological αSYN accumu-
lation induces degeneration in brain areas associated with autonomic
and related non-motor features of MSA.
Parkinsonism and ataxia are generally considered cardinal motor
features of MSA (Gilman et al., 2008; Stefanova et al., 2009a). How-
ever, MSA patients often develop AF and other non-motor features as
well (Lipp et al., 2009). Although symptomatic therapies for cardiovas-
cular autonomic and urogenital failure are available, health-related
quality of life remains signiﬁcantly impaired and deteriorates over time
(Kollensperger et al., 2007). The lack of effective therapeutic options in
MSA-associated AF generates a strong need for appropriate preclinical
testbeds replicating MSA-like central ANS neuropathology resulting in
quantiﬁable functional markers.
Transgenic overexpression of α1B-adrenergic receptors (α1B-AR) in
mice generated wide-spread neurodegeneration linked to seizures
(Zuscik et al., 2000; Kunieda et al., 2002), as well as cardiovascular auto-
nomic dysfunction and motor impairment resembling MSA. This pheno-
type was associated with the formation of neuronal and oligodendroglial
αSYN inclusions by yet unclear mechanisms (Papay et al., 2002; Zuscik
et al., 2000, 2001). More recent evidence of increasedMSA risk conferred
by polymorphisms within the αSYN gene (Scholz et al., 2009; Al-Chalabi
et al., 2009) corroborates the validity of the transgenicαSYNMSAmodels
(Stefanova et al., 2005b). In our previouswork on the (PLP)-αSYNmouse
model we have focused on the motor phenotype and its pathogenesis
(Stefanova et al., 2005a, 2007). Our data suggested a relationship between
oligodendroglialαSYN overexpression, neuroinﬂammation and oxidative
stress resulting in degeneration of striatonigral and olivopontocerebellarpathways that are typically affected in MSA. The model proved to be a
powerful testbed for preclinical drug screening of candidate neuropro-
tective agents (Stefanova et al., 2008; Schapira, 2008). Further, transplan-
tation of embryonic striatal tissue in the (PLP)-αSYN mouse model has
recently identiﬁed evidence thatαSYN aggregatesmay compromise graft
maturation and integration (Stefanova et al., 2009b; Kordower and
Brundin, 2009).Whether the ANS is affected in the transgenicαSYNMSA
models has not been addressed so far.
The present ﬁndings indicate that αSYN overexpression in oligo-
dendrocytes of (PLP)-αSYN mice augments age-dependent loss of
neurons in cholinergic brainstem nuclei such as NAmb, LDT and PPT.
Further, spinal αSYN pathology in (PLP)-αSYN mice leads to early
progressive loss of neurons in Onuf's nucleus, whereas the age-related
decline of IML neurons appeared unaffected by oligodendroglial αSYN
pathology.
NAmb, LDT and PPT have been identiﬁed and extensively charac-
terized in the mouse CNS in terms of structure and function. These
murine nuclei show various degrees of selective vulnerability to dif-
ferent inductors of neurodegeneration. For example, injury of meso-
pontine cholinergic neurons in PPT and LDT can be induced by abnormal
β-amyloid peptide expression in transgenic mice and appears to be
associated with REM sleep perturbations relevant to AD (Zhang et al.,
2005). Neuronal degeneration of NAmb associated with dysregulation
of heart rate controlmay be observed in diabetic mice (Yan et al., 2009).
Further, selective motoneuron pathology with preservation of the
murine analogue of Onuf's nucleus was reported in a model of amyo-
trophic lateral sclerosis, intriguingly replicating the human disease
(Hamson et al., 2002). Based on our current ﬁndings in the (PLP)-αSYN
mice and the available knowledge on the functional correlate of
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cardiovascular, urogenital and REM sleep disturbances resulting from
the oligodendroglial overexpression of humanαSYN in the (PLP)-αSYN
mice. These functional deﬁcits will be characterized in a separate study
using established methods (Zhang et al., 2005; Yan et al., 2009).
MSA is often associated with neuronal loss in IML, indeed this
striking neuropathological feature has been highlighted by Shy and
Drager (1960) in their landmark study. In thoracic IML of healthy
persons, the number of preganglionic sympathetic neurons decreases
with aging (Sakajiri et al., 1996) similar to our current observation in
non-tg mouse IML. In the (PLP)-αSYN mouse oligodendroglial αSYN-
overexpression induced neurodegeneration of the Onuf's nucleus ana-
loguewithout signiﬁcantly affecting age-related attrition of IMLpregan-
glionic sympathetic neurons. Remarkably, IMLpathology in humanMSA
may be variable with little or no involvement in some cases and severe
degeneration in others (Wenning et al., 1997; Kobayashi et al., 1998;
Yoshida, 2007). The discordant effects of αSYN inclusion pathology on
rates of neuronal loss seen in our study suggest that oligodendroglial
αSYN overexpression may augment inherent age-related vulnerability
patterns within the murine ANS. It is therefore conceivable that we
might have observed aggravated IML pathology in older tg mice.
Our results corroborate the utility of the (PLP)-αSYN MSA model
which replicates important non-motor andmotor aspects of the human
disease (Table 1). In contrast to other transgenic MSAmodels (Table 2),
the (PLP)-αSYNmodel represents a unique phenotype expressingmild
degrees of motor and autonomic pathology reminiscent of early-stage
human MSA, thus providing a useful testbed for the screening of novel
disease-modifying interventions (Stefanova et al., 2007). Further,αSYN
mediated neurodegeneration can be strikingly exacerbated in (PLP)-
αSYN mice by challenge with oxidative stress resulting in a model of
end-stage MSA that features severe striatonigral degeneration and
olivopontocerebellar pathology, the substrate of the MSA-associatedTable 2
Comparative overview of existing murine transgenic models of MSA summarizing salient b
Transgenic mouse
model of MSA
Genetic design Behaviour
(PLP)-αSYN Human αSYN overexpression
under the PLP promoter
Shortened stride length
Exacerbated phenotype
with impaired rearing, pole test
hindlimb and truncal
dystonia, bradikinesia
(MBP)-αSYN Human αSYN overexpression
under the MBP promotor
Tremor
Ataxia
Impaired rotarod
and pole test
Seizures
(CNP)-αSYN Human αSYN overexpression
under the CNP promotor
Impaired rotarod performance
Impaired wire hanging
α1B-AR α1B-AR overexpression under
the mouse α1B-AR promoter
Decreased horizontal ambulatio
Decreased rearing (partly rever
by L-DOPA)
Tremor
Seizures
Decreased heart rate
Hypotension
Increased in vivo spontaneous
interictal epileptogenicity
and EEG/behavioural seizures
αSYN, α-synuclein; α1B-AR, α1B adrenergic receptor; PLP, proteolipid protein; MBP, my
cytoplasmic inclusions; SNc, substantia nigra pars compacta; LC, locus coeruleus; NAmb, nuc
nucleus; SND, striatonigral degeneration; OPCA, oligopontocerebellar atrophy; TH, tyrosinemotor disorder (Stefanova et al., 2005a). It is likely that central
autonomic degeneration as demonstrated here in unchallenged (PLP)-
αSYN can also be augmented and extended following oxidative stress,
generating a murine analogue of severe MSA. An ongoing study in our
laboratory aims to determine possible functional correlates of auto-
nomic failure in (PLP)-αSYN mice including indices of cardiac, urinary
and sleep disturbance. Although functional correlates of the autonomic
degeneration pattern remain to be determined two major conclusions
can be drawn from our current study: 1) In addition to our previous
work demonstrating a mild but robust Parkinson-like phenotype with
midbrain degeneration in (PLP)-αSYN mice we now show that abnor-
mal αSYN expression in oligodendrocytes induces degeneration of
MSA-linked autonomic and non-motor centers. These ﬁndings support
the hypothesis of a primary αSYN oligodendrogliopathy in MSA
resulting in selective neuronal multisystemdegeneration. They further
highlight the utility of the current model as a preclinical testbed for
novel therapeutic strategies targeting both autonomic and motor
aspects of MSA. 2) The relative preservation of IML despite exposure
to αSYN inclusion pathology suggests differential interactions of αSYN
toxicity and subregional neuronal vulnerabilities within the ANS. In
summary, the (PLP)-αSYN transgenic MSA model provides a powerful
tool that can be further exploited to dissect pathogeneticmechanismsof
glioneurodegeneration in MSA thereby identifying novel targets for
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